Christopher N. Mores

Christopher N. Mores

Auto-generated profile, based on publicly available information

Christopher N. Mores

Department of Global Health, Milken Institute School of Public Health, George Washington University, Washington, DC 20052, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2021 in Nature Immunology
Verified
Journal Article
Open access
PDF file
VDVincent Dussupt
Vincent Dussupt
RSRajeshwer S. Sankhala
Rajeshwer S. Sankhala
LMLetzibeth Mendez-Rivera
Letzibeth Mendez-Rivera
STSamantha M. Townsley
Samantha M. Townsley
FSFabian Schmidt
Fabian Schmidt
SKShelly J. Krebs
Shelly J. Krebs
Prevention of viral escape and increased coverage against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal antibodies (mAbs) targeting multiple sites of vulnerability on the coronavirus spike glycoprotein. Here we identify several potent neutralizing antibodies directed against either the N-terminal domain (NTD) or the receptor-binding domain (RBD) of the spike protein. Administered in combinations, these mAbs provided low-dose protection against SARS-CoV-2 infection in the K18-human angiotensin-converting enzyme 2 mouse model, using both neutralization and Fc effector antibody functions. The RBD mAb WRAIR-2125, which targets residue F486 through a unique heavy-chain and light-chain pairing, demonstrated potent neutralizing activity against all major SARS-CoV-2 variants of concern. In combination with NTD and other RBD mAbs, WRAIR-2125 also prevented viral escape. These data demonstrate that NTD/RBD mAb combinations confer potent protection, likely leveraging complementary mechanisms of viral inactivation and clearance.

8 April 2020 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
MMMichael K McCracken
Michael K McCracken
GGGregory D Gromowski
Gregory D Gromowski
LGLindsey S Garver
Lindsey S Garver
BGBrad A Goupil
Brad A Goupil
KWKathryne D Walker
Kathryne D Walker
LWLucile Warter
Lucile Warter
Dengue virus (DENV) is transmitted by infectious mosquitoes during blood-feeding via saliva containing biologically-active proteins. Here, we examined the effect of varying DENV infection modality in rhesus macaques in order to improve the DENV nonhuman primate (NHP) challenge model. NHPs were exposed to DENV-1 via subcutaneous or intradermal inoculation of virus only, intradermal inoculation of virus and salivary gland extract, or infectious mosquito feeding. The infectious mosquito feeding group exhibited delayed onset of viremia, greater viral loads, and altered clinical and immune responses compared to other groups. After 15 months, NHPs in the subcutaneous and infectious mosquito feeding groups were re-exposed to either DENV-1 or DENV-2. Viral replication and neutralizing antibody following homologous challenge were suggestive of sterilizing immunity, whereas heterologous challenge resulted in productive, yet reduced, DENV-2 replication and boosted neutralizing antibody. These results show that a more transmission-relevant exposure modality resulted in viral replication closer to that observed in humans. Dengue virus is transmitted into the skin of humans by mosquitoes as they take a blood meal. In contrast, many animal models are infected in the laboratory using a syringe to inject below the skin. Here, we looked at how different routes and methods of infection altered dengue infection in rhesus macaques. We found that infection via mosquito feeding resulted in a number of changes compared to other routes and methods, including a delay in the time to detection of dengue virus and overall greater quantities of dengue virus in the blood, and changes in the amounts of various components of blood that have been associated with dengue disease in humans. After 15 months, we exposed the macaques again to either the same or a different type of dengue virus. We found that animals exposed to the same type of dengue virus were protected from infection, whereas those animals exposed to a different type were only partially protected. Overall, our results show that dengue virus delivery using the natural transmission vector, mosquitoes, results in infection that is closer to what is observed in humans and may influence the interpretation of future studies of candidate vaccines.

21 October 2015 in Vaccine
Verified
Journal Article
Closed access
RCRebecca Christofferson
Rebecca Christofferson
CMChristopher N. Mores
Christopher N. Mores

21 May 2021 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
TLThomas Sean Lendvay
Thomas Sean Lendvay
JCJames Chen
James Chen
BHBrian H. Harcourt
Brian H. Harcourt
FSFlorine Scholte
Florine Scholte
YLYing Ling Lin
Ying Ling Lin
MCMay C. Chu
May C. Chu
Objective: The coronavirus disease 2019 (COVID-19) pandemic has resulted in shortages of personal protective equipment (PPE) underscoring the urgent need for simple, efficient, and inexpensive methods to decontaminate SARS-CoV-2-exposed masks and respirators. We hypothesized that methylene blue (MB) photochemical treatment, which has various clinical applications, could decontaminate PPE contaminated with coronavirus. Design: The two arms of the study included: 1) PPE inoculation with coronaviruses followed by MB with light (MBL) decontamination treatment, and 2) PPE treatment with MBL for 5 cycles of decontamination (5CD) to determine maintenance of PPE performance. Methods: MBL treatment was used to inactivate coronaviruses on three N95 filtering facepiece respirator (FFR) and two medical mask (MM) models. We inoculated FFR and MM materials with three coronaviruses, including SARS-CoV-2, and treated with 10 µM MB and exposed to 50,000 lux of white light or 12,500 lux of red light for 30 minutes. In parallel, integrity was assessed after 5CD using multiple US and international test methods and compared to the FDA-authorized vaporized hydrogen peroxide plus ozone (VHP+O3) decontamination method. Results: Overall, MBL robustly and consistently inactivated all three coronaviruses with 99.8 - to >99.9% virus inactivation across all FFRs and MMs tested. FFR and MM integrity was maintained after 5 cycles of MBL treatment, whereas one FFR model failed after 5 cycles of VHP+O3. Conclusions: MBL treatment decontaminated respirators and masks by inactivating three tested coronaviruses without compromising integrity through 5CD. MBL decontamination is effective, low-cost and does not require specialized equipment, making it applicable in all-resource settings.

23 September 2019 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
KSKathryn L. Schaber
Kathryn L. Schaber
VPValerie A Paz-Soldán
Valerie A Paz-Soldán
AMAmy C. Morrison
Amy C. Morrison
WEWilliam H. D. Elson
William H. D. Elson
ARAlan L. Rothman
Alan L. Rothman
GVGonzalo M. Vazquez-Prokopec
Gonzalo M. Vazquez-Prokopec
Human mobility plays a central role in shaping pathogen transmission by generating spatial and/or individual variability in potential pathogen-transmitting contacts. Recent research has shown that symptomatic infection can influence human mobility and pathogen transmission dynamics. Better understanding the complex relationship between symptom severity, infectiousness, and human mobility requires quantification of movement patterns throughout infectiousness. For dengue virus (DENV), human infectiousness peaks 0–2 days after symptom onset, making it paramount to understand human movement patterns from the beginning of illness. Through community-based febrile surveillance and RT-PCR assays, we identified a cohort of DENV+ residents of the city of Iquitos, Peru (n = 63). Using retrospective interviews, we measured the movements of these individuals when healthy and during each day of symptomatic illness. The most dramatic changes in mobility occurred during the first three days after symptom onset; individuals visited significantly fewer locations (Wilcoxon test, p = 0.017) and spent significantly more time at home (Wilcoxon test, p = 0.005), compared to when healthy. By 7–9 days after symptom onset, mobility measures had returned to healthy levels. Throughout an individual’s symptomatic period, the day of illness and their subjective sense of well-being were the most significant predictors for the number of locations and houses they visited. Our study is one of the first to collect and analyze human mobility data at a daily scale during symptomatic infection. Accounting for the observed changes in human mobility throughout illness will improve understanding of the impact of disease on DENV transmission dynamics and the interpretation of public health-based surveillance data. Dengue is the most important mosquito-borne viral disease of humans worldwide. Due to the limited mobility of the mosquitoes that transmit dengue virus, human mobility can be a key to both understanding an individual’s exposure to the virus and explaining the spread of dengue throughout a population. Accurate disease models should include human mobility; however, changes in human movement patterns due to the presence of symptoms need to be taken into account. We quantified the impact of symptom presence on human mobility throughout the infectious period by analyzing a dataset on the daily movements of dengue virus infected individuals. Accounting for these changing patterns of mobility will improve understanding of the complex relationship between symptom severity, human movement, and dengue virus transmission. Furthermore, dengue transmission models that incorporate symptom-driven mobility changes can be used to evaluate scenarios and strategies for disease prevention.

21 September 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
Aileen ChangAileen Chang
Aileen Chang
STSarah R. Tritsch
Sarah R. Tritsch
APAbigail J. Porzucek
Abigail J. Porzucek
ASArnold Schwartz
Arnold Schwartz
MSMargaux Seyler-Schmidt
Margaux Seyler-Schmidt
CMChristopher N. Mores
Christopher N. Mores
Chikungunya virus (CHIKV) was introduced to the Americas in 2013, causing two million infections across over thirty countries. CHIKV causes a chronic debilitating arthritis in one fourth of infected individuals and currently evidence-based targeted therapies for the treatment of CHIKV arthritis are lacking. Multiple mouse models of chikungunya have been developed to study acute CHIKV infection. In humans, post-CHIKV arthritis may persist for months to years after viremia from a CHIKV infection has resolved. Therefore, the development of a mouse model of post-acute arthritis of chikungunya may facilitate the study of potential novel therapeutics for this arthritis. In this article we describe the development of a wild-type immunocompetent C57BL/6 mouse model for post-acute arthritis of chikungunya, including a histologic inflammation scoring system, as well as suggestions for how this mouse model may be used to examine the efficacy of novel therapies for CHIKV arthritis.